Sorry to see you go. You had been around here for quite a while but, you know what is best for you.
I understand where you're coming from. As much as I defended Punit in the past, I now realize that most of the blame for the situation OncoSec is in has to be pinned on him. He dropped the ball, maybe more than once, when it came to finding a suitable BP for a potential buyout of OncoSec.
With all the articles written about OncoSec that put it at the forefront of its field, it had plenty of exposure. It had heavyweights, such as Robert Pierce, doing its cutting-edge research.
Yet, the market never liked OncoSec. There seemed to be something wrong with the company. I'm not sure if whatever wrong had to do with trial data or not but, one thing is for sure: One obvious thing that was wrong with OncoSec was the lack of action on the part of Punit.
I sincerely wish you the best.
$ONCS
News 
Market Data 
Discover 
AI
